Skip to content
DataLookout
Menu

MyVisionNCT07463521

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 29 → 36 locations
  2. Minor Trial sites expanded: 14 → 29 locations
  3. Minor Study sites: 14 to 15
  4. Notable Eligibility criteria expanded, about 23 words
    • Trial sites expanded: 11 → 14 locations
    • Secondary endpoints: details revised at 6 of 7 entries
  5. Minor Trial sites expanded: 7 → 11 locationsv5
  6. Minor Trial sites expanded: 2 → 7 locationsv4
  7. Notable Recruitment opened
    • Study sites: 0 to 2
    • Start date changed from estimate of May 29, 2026 to May 27, 2026
    v3
  8. Minor Study title revisedv2
  9. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part)
Timeframe: At Day 43

Secondary (7)

Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular subdomain score
Change from Baseline at Day 43 in Myasthenia Gravis Impairment Index (MGII) ocular score (Physical Examination part)
Incidence of treatment-emergent adverse events (TEAEs)
Show 2 moreShow less
Incidence of treatment-emergent serious adverse events (TESAEs)
Incidence of TEAEs leading to permanent withdrawal of study treatment

Arms and interventions

RozanolixizumabExperimental

After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive rozanolixizumab. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study.

PlaceboPlacebo comparator

After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive placebo. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study.

Drugs: Rozanolixizumab, Placebo

Sites

36 sites in 9 countries

China 7, Spain 7, United States 6, France 5, Poland 4, Japan 3, Georgia 2, Canada 1, Germany 1